ARMO BioSciences' Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the FDA

The FDA has granted the ARMO Biosciences’ drug candidate, AM0010, orphan drug designation for the treatment of pancreatic cancer.

The FDA has also granted fast track designation for AM0010 in combination with Folfox as a second line therapy in patients with advanced metastatic pancreatic cancer.

“AM0010 has been shown to engage the immune system to induce comprehensive T-cell activation and objective tumor responses in cancer patients with advanced malignancies,” the company said.